From R&D to Phase III: Peptide 39AA Project Completed in 10 Months-Case Studies & Whitepapers-End-to-end CDMO | Porton Pharma Solutions

CN

Case Studies & Whitepapers2024-09-18

From R&D to Phase III: Peptide 39AA Project Completed in 10 Months

With strict project planning and implementation, the research and development of 45AA straight chain peptide was completed in 2 months, and the subsequent production and quality testing of non-GMP (300g) and GMP (1kg) batches were successfully completed in the following 8 months.  The maximum single impurity of the final product does not exceed 0.5%, and the total yield reaches 30%. All manufacturing and quality control are carried out in accordance with GMP requirements, ensuring the q
Read more
Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2024 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2024 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200

To access the complete page, kindly fill out this form.

First Name*
Last Name*
Business Email*
Company*
Department*
Job title*
Continent*
By clicking “Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.
Submit